(Reuters) -U.S. federal health agencies on Tuesday recommended pausing the use of Johnson & Johnson’s single-dose COVID-19 vaccine after six recipients developed a rare disorder involving blood clots.
The U.S. Centers for Disease Control and Prevention will hold an advisory meeting on Wednesday to review the cases.
All the six recipients were women between the ages of 18 and 48. One woman died and a second in Nebraska has been hospitalized in critical condition, the New York Times reported, citing officials. (nyti.ms/3g70oLK)
The CDC and the U.S. Food and Drug Administration said in a joint statement that the adverse events appear to be extremely rare right now.
As of April 12, more than 6.8 million doses of the Johnson & Johnson vaccine have been administered in the United States.
The company’s shares were down 3% before the opening bell.
The move from the U.S. regulators comes less than a week after Europe’s drugs regulator said it was reviewing rare blood clots in four people in the United States who received the shot.
Reporting by Manas Mishra in Bengaluru; Editing by Maju Samuel and Sriraj Kalluvila
Our Standards: The Thomson Reuters Trust Principles.
면책 조항: 본 게시글에 표현된 견해는 전적으로 작성자의 견해이며 Followme의 공식 입장을 대변하지 않습니다. Followme는 제공된 정보의 정확성, 완전성 또는 신뢰성에 대해 책임을 지지 않으며, 서면으로 명시적으로 언급되지 않는 한 해당 내용을 기반으로 취해진 어떠한 조치에 대해서도 책임을 지지 않습니다.
더 오래된 의견은 없습니다. 소파를 가장 먼저 잡으십시오.